Tillman Gerngross' Covid-19 antibody moonshot scores $336M with the help of new ace CFO. Is an IPO next?

Kyle Blankenship

Less than a year into its existence, serial biotech entrepreneur Tillman Gerngross’ antibody play Adagio has raced ahead into a pivotal trial for its lead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Tillman Gerngross' Covid-19 antibody moonshot scores $336M with the help of new ace CFO. Is an IPO next?

Kyle Blankenship

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron plans to buy 23andMe for $256M

David Liu, Sam Sternberg unveil new way to insert big genes in human cells

Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Till­man Gern­gross' Covid-19 an­ti­body moon­shot scores $336M with the help of new ace CFO. Is an IPO next?

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Tillman Gerngross' Covid-19 antibody moonshot scores $336M with the help of new ace CFO. Is an IPO next?